Michael A. Curran
The University of Texas MD Anderson Cancer Center · 420 works · 11,927 citations · h-index 49
Top works
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- PD-L1 Expression in Triple-Negative Breast Cancer
- Tumor Vaccines Expressing Flt3 Ligand Synergize with CTLA-4 Blockade to Reject Preimplanted Tumors
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
- Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- Development of Immunotherapy Combination Strategies in Cancer
- Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
- Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
- 325 Eliminating tumor immune privilege through immune checkpoint cytoreduction
- Efficient Transduction of Nondividing Cells by Optimized Feline Immunodeficiency Virus Vectors
- Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
- Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications